OncoSec Medical (NASDAQ:ONCS) Downgraded by StockNews.com

StockNews.com cut shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

OncoSec Medical Stock Performance

NASDAQ ONCS opened at $0.45 on Tuesday. The firm has a 50-day moving average of $1.18 and a 200-day moving average of $2.62. The stock has a market cap of $1.34 million, a PE ratio of -0.03 and a beta of 1.98. OncoSec Medical has a 52-week low of $0.40 and a 52-week high of $20.68.

OncoSec Medical (NASDAQ:ONCS – Get Rating) last released its quarterly earnings results on Monday, March 13th. The biotechnology company reported ($2.65) EPS for the quarter.

Hedge Funds Weigh In On OncoSec Medical

A number of hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP bought a new position in OncoSec Medical during the fourth quarter worth about $35,000. Renaissance Technologies LLC increased its holdings in OncoSec Medical by 48.8% in the 2nd quarter. Renaissance Technologies LLC now owns 72,898 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 23,900 shares during the period. FNY Investment Advisers LLC bought a new position in OncoSec Medical in the 1st quarter valued at about $272,000. Finally, Bank of New York Mellon Corp increased its holdings in OncoSec Medical by 653.7% in the 1st quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 334,849 shares during the period.

About OncoSec Medical

(Get Rating)

OncoSec Medical, Inc is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.